{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:08:34Z","timestamp":1788847714321,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"S.V. by the Swiss Academy of Medical Sciences\/Gottfried and Julia Bangerter-Rhyner-Foundation","award":["YTCR 58\/20"],"award-info":[{"award-number":["YTCR 58\/20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A subset of patients with advanced-stage melanoma with brain metastases responds intracranially to immune-checkpoint inhibitors (ICIs). We reasoned that features of the spatial architecture of the tumor microenvironment correlate with treatment responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used highly multiplexed single-cell imaging to characterize the TME in 44 samples of MBM patients; both treatment na\u00efve subjects and subjects who had received ICI were included in the cohort. Samples were stained with a 42-plex metal-isotope tagged antibody panel and subsequently imaged using imaging mass cytometry. Downstream analysis focused on phenotypic and spatial characteristics of the tumor microenvironments of ICI responders and non-responders and on correlations of protein expression with overall and local progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Single-cell phenotyping identified more than 1.1 million cells, predominantly tumor (67%) and immune cells (29%). ICI responders exhibited higher baseline proportions of B cells, IDO+ macrophages, and specific T cell subsets (regulatory and exhausted\/activated CD8+). Conversely, neutrophil infiltration was negatively associated with intracranial response and survival. Spatial analysis revealed that responders possess a more localized, clustered immune cell pattern compared to the dispersed patterns seen in non-responders. Modeling CD8+ T cell distribution showed that localized infiltration was positively associated with overall and local progression-free survival, while dispersed patterns correlated with poorer outcomes. Furthermore, ICI-pretreated samples showed higher immune-tumor co-localization than treatment-na\u00efve samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our single-cell, spatially resolved characterization of the tumor microenvironment of human melanoma brain metastases demonstrated distinct phenotypic and spatial infiltration patterns of various immune cells that are associated with ICI response and survival outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag128","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:48:11Z","timestamp":1779882491000},"page":"2211-2223","source":"Crossref","is-referenced-by-count":1,"title":["Spatially-resolved single-cell imaging of melanoma brain metastases identifies localized immune patterns predictive of immune checkpoint blockade response"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1514-1442","authenticated-orcid":false,"given":"Stefanos","family":"Voglis","sequence":"first","affiliation":[{"name":"Department of Quantitative Biomedicine, University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Institute of Molecular Health Sciences, ETH Zurich , Zurich,","place":["Switzerland"]},{"name":"Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-1678","authenticated-orcid":false,"given":"Daniel","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Quantitative Biomedicine, University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Institute of Molecular Health Sciences, ETH Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4711-1176","authenticated-orcid":false,"given":"Nils","family":"Eling","sequence":"additional","affiliation":[{"name":"Department of Quantitative Biomedicine, University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Institute of Molecular Health Sciences, ETH Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-8951","authenticated-orcid":false,"given":"Natalie","family":"De Souza","sequence":"additional","affiliation":[{"name":"Department of Quantitative Biomedicine, University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Institute of Molecular Health Sciences, ETH Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-4474","authenticated-orcid":false,"given":"Luca","family":"Regli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2828-4706","authenticated-orcid":false,"given":"Marian Christoph","family":"Neidert","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, HOCH Health Ostschweiz, Cantonal Hospital of St. Gallen , St. Gallen,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Czabanka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Frankfurt, Goethe University Frankfurt , Frankfurt,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Mihic-Probst","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-9420","authenticated-orcid":false,"given":"Mitchell","family":"Levesque","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Bodenmiller","sequence":"additional","affiliation":[{"name":"Department of Quantitative Biomedicine, University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Institute of Molecular Health Sciences, ETH Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026090801525160100_noag128-B1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026090801525160100_noag128-B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026090801525160100_noag128-B3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF02782192","article-title":"Long-term survival with metastatic cancer to the brain","volume":"17","author":"Hall","year":"2000","journal-title":"Med Oncol"},{"key":"2026090801525160100_noag128-B4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090801525160100_noag128-B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090801525160100_noag128-B6","doi-asserted-by":"publisher","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026090801525160100_noag128-B7","doi-asserted-by":"publisher","first-page":"40836","DOI":"10.18632\/oncotarget.5696","article-title":"Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases","volume":"6","author":"Harter","year":"2015","journal-title":"Oncotarget"},{"key":"2026090801525160100_noag128-B8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"2026090801525160100_noag128-B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrclinonc.2015.237","article-title":"Melanoma in 2015: immune-checkpoint blockade: durable cancer control","volume":"13","author":"Buchbinder","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090801525160100_noag128-B10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"2026090801525160100_noag128-B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090801525160100_noag128-B12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090801525160100_noag128-B13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/J.CELL.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"2026090801525160100_noag128-B14","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","article-title":"Dissecting the treatment-naive ecosystem of human melanoma brain metastasis","volume":"185","author":"Biermann","year":"2022","journal-title":"Cell"},{"key":"2026090801525160100_noag128-B15","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/2326-6066.CIR-21-0870\/704915\/AM\/MICROENVIRONMENTAL-LANDSCAPE-OF-HUMAN-MELANOMA","article-title":"Micro\u00adenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition","volume":"10","author":"Alvarez-Breckenridge","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026090801525160100_noag128-B16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41568-023-00657-4","article-title":"Multiplex protein imaging in tumour biology","volume":"24","author":"de Souza","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026090801525160100_noag128-B17","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/2159-8290.CD-23-1165","article-title":"Highly multiplexed tissue imaging in precision oncology and translational cancer research","volume":"14","author":"Bollhagen","year":"2024","journal-title":"Cancer Discov"},{"key":"2026090801525160100_noag128-B18","doi-asserted-by":"publisher","first-page":"eabk1692","DOI":"10.1126\/sciimmunol.abk1692","article-title":"Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy","volume":"7","author":"Hoch","year":"2022","journal-title":"Sci Immunol"},{"key":"2026090801525160100_noag128-B19","doi-asserted-by":"publisher","first-page":"e270-8","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026090801525160100_noag128-B20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","article-title":"Compensation of signal spillover in suspension and imaging mass cytometry","volume":"6","author":"Chevrier","year":"2018","journal-title":"Cell Syst"},{"key":"2026090801525160100_noag128-B21","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1038\/s41596-023-00881-0","article-title":"An end-to-end workflow for multiplexed image processing and analysis","volume":"18","author":"Windhager","year":"2023","journal-title":"Nat Protoc"},{"key":"2026090801525160100_noag128-B22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","article-title":"Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning","volume":"40","author":"Greenwald","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026090801525160100_noag128-B23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nbt.4091","article-title":"Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors","volume":"36","author":"Haghverdi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2026090801525160100_noag128-B24","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1093\/bioinformatics\/btaa1061","article-title":"cytomapper: an R\/bioconductor package for visualization of highly multiplexed imaging data","volume":"36","author":"Eling","year":"2021","journal-title":"Bioinformatics"},{"key":"2026090801525160100_noag128-B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2026090801525160100_noag128-B26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nmeth.4391","article-title":"histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data","volume":"14","author":"Schapiro","year":"2017","journal-title":"Nat Methods"},{"key":"2026090801525160100_noag128-B27","author":"R Core Team","year":"2024"},{"key":"2026090801525160100_noag128-B28","author":"Team Rs","year":"2020"},{"key":"2026090801525160100_noag128-B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40478-025-02007-x","article-title":"Identification and characterization of tertiary lymphoid structures in brain metastases","volume":"13","author":"Mughal","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"2026090801525160100_noag128-B30","doi-asserted-by":"publisher","first-page":"674565","DOI":"10.3389\/fimmu.2021.674565","article-title":"Tertiary lymphoid structures as a predictive biomarker of response to cancer immunotherapies","volume":"12","author":"Tr\u00fcb","year":"2021","journal-title":"Front Immunol"},{"key":"2026090801525160100_noag128-B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169314","article-title":"Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors","volume":"133","author":"Sun","year":"2023","journal-title":"J Clin Invest"},{"key":"2026090801525160100_noag128-B32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"2026090801525160100_noag128-B33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"2026090801525160100_noag128-B34","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026090801525160100_noag128-B35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2026090801525160100_noag128-B36","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"2026090801525160100_noag128-B37","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090801525160100_noag128-B38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026090801525160100_noag128-B39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"2026090801525160100_noag128-B40","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026090801525160100_noag128-B41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s43018-026-01114-5","article-title":"Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC","volume":"7","author":"Greenwald","year":"2026","journal-title":"Nat Cancer"},{"key":"2026090801525160100_noag128-B42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41590-021-01120-y","article-title":"Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses","volume":"23","author":"Bruchard","year":"2022","journal-title":"Nat Immunol"},{"key":"2026090801525160100_noag128-B43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"2026090801525160100_noag128-B44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag128\/68428414\/noag128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/9\/2211\/68428414\/noag128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/9\/2211\/68428414\/noag128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:52:58Z","timestamp":1788846778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/9\/2211\/8697700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag128","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,28]]}}}